IL-33/sST2 signaling pathway in pulmonary thromboembolism: A clinical observational study.

Autor: Yadigaroğlu M; Samsun University, Faculty of Medicine, Department of Emergency Medicine, Samsun, Turkey. Electronic address: metin.yadigaroglu@samsun.edu.tr., Güzel M; Samsun University, Faculty of Medicine, Department of Emergency Medicine, Samsun, Turkey. Electronic address: murat.guzel@samsun.edu.tr., Erdem E; Şırnak State Hospital, Department of Emergency Medicine, Şırnak, Turkey. Electronic address: elifkaraca5561@gmail.com., Görgün S; Samsun Education and Research Hospital, Department of Microbiology and Clinical Microbiology, Samsun, Turkey. Electronic address: selimgorgun55@gmail.com., Aksu EA; Samsun University, Faculty of Medicine, Department of Chest Diseases, Samsun, Turkey. Electronic address: esra.aksu@samsun.edu.tr., Ocak M; Samsun University, Faculty of Medicine, Department of Emergency Medicine, Samsun, Turkey. Electronic address: metin.ocak@samsun.edu.tr., Yadigaroğlu NÖ; Samsun University, Faculty of Medicine, Department of Internal Medicine, Samsun, Turkey. Electronic address: nurcinogreten@gmail.com., Demir MT; Samsun Education and Research Hospital, Department of Emergency Medicine, Samsun, Turkey. Electronic address: mehmetevfik@yahoo.com., Yücel M; Samsun University, Faculty of Medicine, Department of Emergency Medicine, Samsun, Turkey. Electronic address: murat.yucel@samsun.edu.tr.
Jazyk: angličtina
Zdroj: Cytokine [Cytokine] 2024 Oct; Vol. 182, pp. 156707. Date of Electronic Publication: 2024 Jul 30.
DOI: 10.1016/j.cyto.2024.156707
Abstrakt: Background: Pulmonary thromboembolism (PTE) is a cardiovascular emergency that can result in mortality. In the interleukin-33 (IL-33) /soluble suppression of tumorigenicity 2 (sST2) signaling pathway, increased sST2 is a cardiovascular risk factor. This study aimed to investigate the effectiveness of biomarkers in the IL-33/sST2 signaling pathway in determining PTE diagnosis, clinical severity, and mortality.
Method: This study was conducted as a single-center, prospective, observational study. Patients admitted to the emergency department and diagnosed with PTE constituted the patient group (n = 112), and healthy volunteers with similar sociodemographic characteristics constituted the control group (n = 62). Biomarkers in the IL-33/sST2 signaling pathway were evaluated for diagnosis, clinical severity, and prognosis.
Results: IL-33 was lower in the patient group than in the control group (275.89 versus 403.35 pg/mL), while sST2 levels were higher in the patient group than in the control group (53.16 versus 11.78 ng/mL) (p < 0.001 and p = 0.001; respectively). The AUC of IL-33 to diagnose PTE was 0.656 (95 % CI: 0.580-0.726). The optimal IL-33 cut-off point to diagnose PTE was ≤304.11 pg/mL (56.2 % sensitivity, 79 % specificity). The AUC of sST2 to diagnose PTE was 0.818 (95 % CI: 0.752-0.872). The optimal sST2 cut-off point to diagnose PTE was >14.48 ng/mL (83 % sensitivity, 71 % specificity). IL-33 levels were lower in patients with mortality (169.85 versus 332.04 pg/mL) compared to patients without mortality, whereas sST2 levels were higher in patients with mortality (118.32 versus 28.07 ng/mL) compared to patients without mortality (p > 0.001 for both). The AUC of IL-33 to predict the mortality of PTE was 0.801 (95 % CI: 0.715-0.870). The optimal IL-33 cut-off point to predict the mortality of PTE was ≤212.05 pg/mL (75 % sensitivity, 79.5 % specificity). The AUC of sST2 to predict the mortality of PTE was 0.824 (95 % CI: 0.740-0.889). The optimal sST2 cut-off point to predict the mortality of PTE was >81 ng/mL (95.8 % sensitivity, 78.4 % specificity).
Conclusion: In the IL-33/ST2 signaling pathway, decreased IL-33 and increased sST2 are valuable biomarkers for diagnosis and prediction of mortality in patients with PTE.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: